CombiMatrix Announces Additional Cooperative Research and Development Agreement with the U.S. Air Force.

NEWPORT BEACH, Calif. -- Acacia Research Corporation (Nasdaq:CBMX)(Nasdaq:ACTG) announced today its CombiMatrix group has established a Cooperative Research and Development Agreement (CRDA) with the U.S. Air Force Research Laboratory, Human Effectiveness Directorate, Biosciences and Protection Division, Applied Biotechnology Branch (AFRL/HEPB). The CRDA will focus on "Development of a Biomonitor Device with Biomarker-based Microarrays."

Under the CRDA, AFRL/HEPB and CombiMatrix will develop a personal health monitoring system utilizing CombiMatrix's CustomArray(TM) technology. The goal of the program is to develop a miniaturized device capable of analyzing multiple biomarkers (either DNA or protein) that would aid the U.S. Department of Defense in its mission to effectively monitor the health status of military service personnel before, during, and after deployment where untoward exposures may impact on their performance or health.

"Collaborating with AFRL/HEPB through this CRDA, provides a means for us to work with investigators who are concerned with Force Health Protection. This program is the result of a Presidential Directive and is focused on monitoring the health of all Service members while they are on active duty," said Dr. David Danley, Director of Homeland Defense for CombiMatrix. "Scientists at AFRL are looking at the relationships of genetics, physiology, and environmental stressors that can reduce human performance or lead to acute or chronic health problems. Our microarray technologies will allow them to take expanded capabilities to the field where adverse events occur and palliative intervention needs to be initiated."

"Our technology continues to gain credibility with our military, as indicated by this new relationship with the U.S. Air Force. This agreement is in addition to our previously announced program with the Air Force Institute of Operational Health," said Dr. Amit Kumar, President and CEO of CombiMatrix. "Going forward we hope to expand and strengthen our relationship with the U.S. Department of Defense, Homeland Security, and other segments of our military."

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 40 patent portfolios, which include over 150 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging, spreadsheet automation, user activated Internet advertising and web conferencing & collaboration software.

Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.